Heron Therapeutics Inc. (NASDAQ:HRTX) – Analysts at Leerink Swann decreased their FY2019 earnings per share (EPS) estimates for Heron Therapeutics in a report issued on Tuesday. Leerink Swann analyst J. Gerberry now expects that the firm will post earnings of $1.04 per share for the year, down from their previous estimate of $1.07. Leerink Swann has a “Buy” rating and a $34.00 price target on the stock.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.07.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Other research analysts have also recently issued research reports about the stock. Brean Capital started coverage on shares of Heron Therapeutics in a research report on Tuesday, October 4th. They issued a “buy” rating and a $41.00 target price on the stock. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 18th. Lake Street Capital reaffirmed a “buy” rating and issued a $45.00 target price on shares of Heron Therapeutics in a research report on Tuesday, September 6th. JMP Securities reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Friday, September 9th. Finally, Jefferies Group decreased their target price on shares of Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 3rd. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $41.63.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded down 4.05% on Thursday, hitting $18.95. 99,518 shares of the stock were exchanged. Heron Therapeutics has a 52-week low of $13.95 and a 52-week high of $31.32. The company’s 50 day moving average is $16.55 and its 200-day moving average is $18.12.

Hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. raised its position in shares of Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock valued at $139,937,000 after buying an additional 229,182 shares in the last quarter. FMR LLC raised its position in shares of Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock valued at $99,156,000 after buying an additional 63,968 shares in the last quarter. Janus Capital Management LLC raised its position in shares of Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock valued at $72,450,000 after buying an additional 516,166 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $49,230,000. Finally, Cormorant Asset Management LLC raised its position in shares of Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock valued at $33,233,000 after buying an additional 64,281 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.